Switch Therapy of Community-Acquired Pneumonia. Results of Cefuroxime and Cefuroxime Axetil Trial

Antibiotiki i Khimioterapiya

Volumn 43, Issue 6, 1998, Pages 7-11

  Yakovlev, S V ^a   Suvorova, M P ^a   Dvoretsky, L I ^a   Vlasenko, N A ^a   Shakhova, T V ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Ceturoxime; Community acquired pneumonia; Switch therapy

Indexed keywords

CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; DRUG DERIVATIVE; PRODRUG;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMMUNICABLE DISEASE; COMPARATIVE STUDY; DRUG ADMINISTRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CEFUROXIME; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PRODRUGS; TREATMENT OUTCOME;

EID: 0031615771     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Finch R.G. Pneumonia: the impact of antibiotic resistance on its management Microbiol Drug Res 1995; 1 149-158
2. Martin R.E., Bates J.H Community-acquired pneumonia. In: Current therapy of infect dis. D. Schlossberg ed. Mosby. St. Louis 1996; 93-96.
3. Van den Brande P., Vondra V., Vogel F. et al. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest 1997; 112. 406-415.
4. Ramirez J.A , Srinath L., Ahkee S. et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-1276.
5. Vogel F Sequential therapy in community-acquired lower respiratory tract infection. Amer J Med 1995; 99 Suppl 6B: 14S-19S
6. Delamonica P Cefuroxime axetil. Intern J Antimicrob Agents 1994, 4: 23-26.
7. Perry C. M., Brogden R.N. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1996; 52 1: 125-158.
8. Bergan T. Pharmacokinetic properties of the cephalosporms. Drugs 1987; 34 Suppl 2: 89-104.
9. Burnakis T.G A cost effective approach to treatment of infection "switch therapy". Hosp Pharm 1992, 27: 353-360
10. Jewesson P. Cost-effectiveness and value of an IV switch. Pharmaco Economics 1994, 5: Suppl 2: 20-26.
11. Shaltt I., Dagan R , Engelgard D et al Cefuroxime efficacy in pneumonia sequential short-course IV/oral suspension therapy Isr J Med Sci 1994; 30: 684-689.